Design and optimization of highly-selective fungal CYP51 inhibitors.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2014-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmcl.2014.05.068PMID 24948565
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Architecture of a single membrane spanning cytochrome P450 suggests constraints that orient the catalytic domain relative to a bilayer

  2014cited by this paper
• Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.

  2014cited by this paper
• Complexes of Trypanosoma cruzi Sterol 14α-Demethylase (CYP51) with Two Pyridine-based Drug Candidates for Chagas Disease

  2013cited by this paper
• Current concepts in antifungal pharmacology.

  2011cited by this paper
• Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations

  2011cited by this paper
• Therapy for fungal diseases: opportunities and priorities.

  2010cited by this paper
• Structural Insights into Inhibition of Sterol 14α-Demethylase in the Human Pathogen Trypanosoma cruzi*

  2010cited by this paper
• Drug interactions during therapy with three major groups of antimicrobial agents

  2006cited by this paper
• Evaluation of Antifungal Efficacy in an Optimized Animal Model of Trichophyton mentagrophytes-Dermatophytosis

  2004cited by this paper
• Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors

  2001cited by this paper
• New antifungal 1,2,4-triazoles with difluoro(heteroaryl)methyl moiety.

  2000cited by this paper
• Novel antifungal 2-aryl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol derivatives with high activity against Aspergillus fumigatus

  1996cited by this paper

• Exploring the Bioactivity of Primary Carbamates: Carbonic Anhydrase Inhibition Profiles, Antioxidant Potential, Antimicrobial Effect, and Molecular Docking Studies

  2026cites this paper
• Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects

  2025cites this paper
• Synthesis of 1,2-Fluorinated Ferrocenes and 1,3-Fluorinated Ferrocenes

  2025cites this paper
• The Significance of Mono‐ and Dual‐Effective Agents in the Development of New Antifungal Strategies

  2025cites this paper
• Sustained Efficacy of Oteseconazole in Women with Recurrent Vulvovaginal Candidiasis

  2025cites this paper
• A Strategy for the Development of New Antimycotics Acting on the Cell Wall and Cell Membrane of Fungi

  2025cites this paper
• Understanding the mechanisms of resistance to azole antifungals in Candida species

  2025cites this paper
• Targeting fungal lipid synthesis for antifungal drug development and potentiation of contemporary antifungals

  2025influential citation
• CHIRAL, FLUORINE-CONTAINING PHARMACEUTICALS

  2025influential citation
• An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013-2023).

  2024cites this paper
• Interdisciplinary approaches for the discovery of novel antifungals.

  2024cites this paper
• Fluorine in the pharmaceutical industry: Synthetic approaches and application of clinically approved fluorine-enriched anti-infectious medications.

  2024cites this paper
• Amphotericin B in the Era of New Antifungals: Where Will It Stand?

  2024cites this paper
• Discovery of a Novel Potent Tetrazole Antifungal Candidate with High Selectivity and Broad Spectrum.

  2024cites this paper
• Cryptococcosis and Cryptococcal Meningitis: A Narrative Review and the Up-to-Date Management Approach

  2024cites this paper
• Synthetic Approaches to the New Drugs Approved During 2022.

  2024cites this paper
• Druggable Sterol Metabolizing Enzymes in Infectious Diseases: Cell Targets to Therapeutic Leads

  2024cites this paper
• Advancements and challenges in antifungal therapeutic development

  2024cites this paper
• A Preliminary Evaluation on the Antifungal Efficacy of VT-1161 against Persister Candida albicans Cells in Vulvovaginal Candidiasis

  2024cites this paper
• Synthesis, antimicrobial properties, hemolytic behavior and molecular docking studies of azole-based steroidal heterocycles

  2024cites this paper
• New Ground in Antifungal Discovery and Therapy for Invasive Fungal Infections: Innovations, Challenges, and Future Directions

  2024cites this paper
• Photoredox-Catalyzed Regioselective 1,3-Alkoxypyridylation of gem-Difluorocyclopropanes.

  2024cites this paper
• Lactoperoxidase Inhibition of Celecoxib Derivatives Containing the Pyrazole Linked‐Sulfonamide Moiety: Antioxidant Capacity, Antimicrobial Activity, and Molecular Docking Studies

  2024cites this paper
• Azole Combinations and Multi-Targeting Drugs That Synergistically Inhibit Candidozyma auris

  2024cites this paper
• Ecotoxicity and Mutagenicity Assessment of Novel Antifungal Agents VT-1161 and T-2307

  2024cites this paper
• Assessment of the potential risk of oteseconazole and two other tetrazole antifungals to inhibit adrenal steroidogenesis and peripheral metabolism of corticosteroids

  2024cites this paper
• Novel targets and improved immunotherapeutic techniques with an emphasis on antimycosal drug resistance for the treatment and management of mycosis

  2024cites this paper
• Oteseconazole: First Approved Orally Bioavailable and Selective CYP51 Inhibitor for the Treatment of Patients with Recurrent Vulvovaginal Candidiasis.

  2023cites this paper
• Analysis of ERG 11 expression in clinical isolates of dermatophytes in patients with resistant Tinea infection.

  2023cites this paper
• Copper‐Catalyzed Regio‐ and Enantioselective Hydroboration of Difluoroalkyl‐Substituted Internal Alkenes

  2023cites this paper
• The intricate link between iron, mitochondria and azoles in Candida species

  2023cites this paper
• A review: FDA-approved fluorine-containing small molecules from 2015 to 2022.

  2023cites this paper
• N-unsubstituted Imidazoles: Design, Synthesis, and Antimicrobial Evaluation.

  2023cites this paper
• The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective

  2023cites this paper
• Strategies of targeting CYP51 for IFIs therapy: Emerging prospects, opportunities and challenges.

  2023cites this paper
• Oteseconazole: a long-awaited diversification of the antifungal arsenal to manage recurrent vulvovaginal candidiasis (RVVC)

  2023influential citation
• Epidemiology, Modern Diagnostics, and the Management of Mucorales Infections

  2023cites this paper
• Azole resistance in Candida auris: mechanisms and combinatorial therapy

  2023cites this paper
• Recent advances in antifungal drug development targeting lanosterol 14α‐demethylase (CYP51): A comprehensive review with structural and molecular insights

  2023cites this paper
• New drug approvals for 2022: Synthesis and clinical applications

  2023cites this paper
• Discovery of Novel Tetrazoles Featuring a Pyrazole Moiety as Potent and Highly Selective Antifungal Agents

  2023cites this paper
• New Approved Drugs Appearing in the Pharmaceutical Market in 2022 Featuring Fragments of Tailor-Made Amino Acids and Fluorine

  2023cites this paper
• Potential Strategies to Control the Risk of Antifungal Resistance in Humans: A Comprehensive Review

  2023cites this paper
• 5,6‐Dihydrotetrazolo[1,5‐c]quinazolines: Toxicity prediction, synthesis, antimicrobial activity, molecular docking, and perspectives

  2023cites this paper
• The binding of nitrogen-donor ligands to the ferric and ferrous forms of cytochrome P450 enzymes.

  2023cites this paper
• VT-1161—A Tetrazole for Management of Mono- and Dual-Species Biofilms

  2023cites this paper
• Synthesis of novel tetrazolic derivatives and evaluation of their antimicrobial activity

  2023cites this paper
• Design, synthesis, and evaluation of novel tetrazoles featuring isoxazole moiety as highly selective antifungal agents.

  2023cites this paper
• Characterisation of Candida parapsilosis CYP51 as a Drug Target Using Saccharomyces cerevisiae as Host

  2022cites this paper
• New Antifungal Agents with Azole Moieties

  2022cites this paper
• Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review

  2022cites this paper
• Efficient selective targeting of Candida CYP51 by oxadiazole derivatives designed from plant cuminaldehyde.

  2022cites this paper
• Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents

  2022cites this paper
• Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis.

  2022cites this paper
• Drug design strategies for the treatment azole-resistant candidiasis

  2022cites this paper
• Therapeutic approaches for combating Aspergillus associated infection.

  2022cites this paper
• Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action

  2022cites this paper
• Reducing the off-target endocrinologic adverse effects of azole antifungals - can it be done?

  2022cites this paper
• Enantio-, Diastereo- and Regioselective Synthesis of Chiral Cyclic and Acyclic gem-Difluoromethylenes by Palladium-Catalyzed [4+2] Cycloaddition.

  2022cites this paper
• Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.

  2022cites this paper
• Antifungal Pipeline

  2021cites this paper
• In Silico Structural Modeling and Analysis of Interactions of Tremellomycetes Cytochrome P450 Monooxygenases CYP51s with Substrates and Azoles

  2021cites this paper
• Azole-Based Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.

  2021cites this paper
• Advances in Antifungal Drug Development: An Up-To-Date Mini Review

  2021cites this paper
• Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis

  2021cites this paper
• Genome mining and In‐silico determination of secondary metabolites of bacteria against Fusarium oxysporum f. sp. Lycopersici

  2021cites this paper
• Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis.

  2021cites this paper
• Structural Insights into the Azole Resistance of the Candida albicans Darlington Strain Using Saccharomyces cerevisiae Lanosterol 14α-Demethylase as a Surrogate

  2021cites this paper
• Tetrazoles

  2021cites this paper
• Novel antifungal agents in clinical trials

  2021cites this paper
• Current and promising pharmacotherapeutic options for candidiasis

  2021influential citation
• Emergomycosis, an Emerging Systemic Mycosis in Immunocompromised Patients: Current Trends and Future Prospects

  2021cites this paper
• Roles for Structural Biology in the Discovery of Drugs and Agrochemicals Targeting Sterol 14α-Demethylases

  2021cites this paper
• History of the development of antifungal azoles: A review on structures, SAR, and mechanism of action.

  2020influential citation
• Fungal Lanosterol 14α-demethylase: A target for next-generation antifungal design.

  2020cites this paper
• An Overview on Conventional and Non-Conventional Therapeutic Approaches for the Treatment of Candidiasis and Underlying Resistance Mechanisms in Clinical Strains

  2020cites this paper
• Aspiring Antifungals: Review of Current Antifungal Pipeline Developments

  2020cites this paper
• Promising antifungal agents: A minireview.

  2020cites this paper
• Potent arylamide derivatives as dual-target antifungal agents: Design, synthesis, biological evaluation, and molecular docking studies.

  2020cites this paper
• Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond.

  2020cites this paper
• Onychomycosis: Novel strategies for treatment

  2020cites this paper
• Innovative therapies for invasive fungal infections in preclinical and clinical development

  2020cites this paper
• Structure-guided approaches to targeting stress responses in human fungal pathogens

  2020cites this paper
• A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis

  2020cites this paper
• Plant-Derived Substances in the Fight Against Infections Caused by Candida Species

  2020cites this paper
• Management of Mucormycosis

  2020cites this paper
• Safety of current therapies for onychomycosis

  2020cites this paper
• Novel Antifungal Agents and Their Activity against Aspergillus Species

  2020cites this paper
• Emerging Issues in Antifungal Resistance.

  2020cites this paper
• Biofilm of Candida albicans: formation, regulation and resistance

  2020influential citation
• A Structural View on Medicinal Chemistry Strategies against Drug Resistance.

  2019cites this paper
• Eine strukturelle Evaluierung medizinalchemischer Strategien gegen Wirkstoffresistenzen

  2019cites this paper
• Onychomycosis: Treatment and prevention of recurrence.

  2019cites this paper
• Synthesis of tetrazole derivatives bearing pyrrolidine scaffold and evaluation of their antifungal activity against Candida albicans.

  2019cites this paper
• Pharmacotherapy for onychomycosis: new and emerging treatments

  2019cites this paper
• Emerging drugs for the treatment of onychomycosis

  2019cites this paper
• New and Promising Chemotherapeutics for Emerging Infections Involving Drug-Resistant Non-albicans Candida Species.

  2019cites this paper
• Synthesis of Chiral Tertiary α,α-Difluoromethyl Carbinols by Cu-Catalyzed Asymmetric Propargylation.

  2019cites this paper
• Impact of the Major Candida glabrata Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161

  2019cites this paper
• Development of Highly Selective Pyrimidine-Based Aldosterone Synthase (CYP11B2) Inhibitors.

  2019cites this paper